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Abstract: Cancer stem cells (CSCs) represent the subpopulation of cancer cells with the ability
to differentiate into other cell phenotypes and initiated tumorigenesis. Previously, we reported
generating CSCs from mouse induced pluripotent stem cells (miPSCs). Here, we investigated the
ability of the CSCs to differentiate into hematopoietic cells. First, the primary cells were isolated from
malignant tumors that were formed by the CSCs. Non-adherent cells (NACs) that arose from adherent
cells were collected and their viability, as well as the morphology and expression of hematopoietic
cell markers, were analyzed. Moreover, NACs were injected into the tail vein of busulfan conditioned
Balb/c nude mice. Finally, CSCs were induced to differentiate to macrophages while using IL3 and
SCF. The round nucleated NACs were found to be viable, positive for hematopoietic lineage markers
and CD34, and expressed hematopoietic markers, just like homing to the bone marrow. When NACs
were injected into mice, Wright–Giemsa staining showed that the number of white blood cells got
higher than those in the control mice after four weeks. CSCs also showed the ability to differentiate
toward macrophages. CSCs were demonstrated to have the potential to provide progenies with
hematopoietic markers, morphology, and homing ability to the bone marrow, which could give new
insight into the tumor microenvironment according to the plasticity of CSCs.
Keywords: Induced pluripotent stem cells; Cancer stem cells differentiation; tumor microenvironment;
hematopoietic cells
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1. Introduction
Cancers have complex architecture, in which the malignant cells interact with non-transformed
cells, forming the tumor microenvironment (TME) [1]. TME is considered to consist of different types
of cells, including fibroblasts, endothelial cells, adipocytes, and immune cells, such as macrophages,
myeloid-derived suppressor cells, and lymphocytes. TME often promotes tumor development in
different stages of carcinogenesis. The identification of different components of TME, to which the
tumor cells respond, could help to understand the chemoresistance in more detail and contribute to
the development of more effective therapy [2,3].
Blood vessels and immune cells are considered as the main components of the TME influencing
the progression and growth of tumors. Different types of leukocytes are known to be present in
many different types of cancers [4,5]. Macrophages are one of the important components of the TME.
Tumor-associated macrophages (TAMs) are located in the tumor, where they support the growth and
progression of tumors by responding and secreting many interleukins and chemokines [6,7]. Recent
studies have revealed that TAMs are not specifically derived from circulating monocytes, but from
embryonic macrophages. Moreover, the origins of TAMs are currently a matter of debate and area for
future research. In this context, leukocytes can interact with cancer cells that are interfering with tumor
progression or promoting tumor growth [8].
On the other hand, cancer stem cells (CSCs) are thought to be responsible for initiating tumors with
the ability to self-renew and differentiation potential. CSCs were detected and isolated from various
cancers, such as liver, pancreatic, brain, breast, colon, and some other tissues, including lymphoma
and leukemia; CSCs also proved to be responsible for chemo-resistance, metastasis, and the relapse of
tumors [9,10].
In the same context, the accumulated data show that CSCs have the ability to differentiate into
multi-lineage, such as pericytes, endothelial cells, and cancer-associated fibroblasts, and they have the
potential to reconstruct their microenvironment by differentiation or recruitment of other cells and,
therefore, contribute to the initiation and progression of cancers [11–13].
Although the immune system and angiogenesis have been shown to have central roles in the
tumorigenesis, the exact relationship between different blood cells and solid cancer stem cells is still
unknown. In this respect, until recently, it was thought that the recruitment of blood and immune cells
from other sites is the way that a tumor constructs its microenvironment, while the ability of cancer
cells in solid tumors to give some types of hematopoietic cells have been reported recently [14–16].
Our lab has developed a CSC model that was converted from mouse induced pluripotent stem
cells (miPSCs). The CSCs derived from miPSCs showed tumorigenicity, differentiation potential, and
self-renewal ability when cultured in the conditioned medium (CM) from cancer cell lines [17]. CM
mimics the cancerous niche, in which miPSCs are exposed to different growth factors and chemokines
secreted from cancer cells. While using this method, we successfully generated CSC models using CM
from lung, pancreas, breast, and liver cancer cell lines [12,17–20]. Furthermore, we showed that our
CSC models could differentiate into vascular endothelial-like cells and cancer-associated fibroblasts,
which support tumor growth in vitro and in vivo. The CSCs exhibited angiogenesis, self-renewal, and
expressed different markers for CSCs associated with undifferentiated state and formed malignant
tumors with metastases. In contrast, miPSCs without treatment formed typical teratomas without
metastasis when transplanted into nude mice.
In this study, we investigated the potential of CSCs to give hematopoietic cells. The morphology
and characteristics of non-adherent cells (NACs) that arise from adherent CSC model were analyzed
while using Giemsa staining, immunofluorescence, and flow cytometry. The ability of NACs homing
to the bone marrow was also assessed in vivo. Furthermore, CSCs were investigated for their ability to
give rise to macrophages by inducing their differentiation with interleukin 3 (IL3) and stem cell factor
(SCF). Our results showed that CSCs might be a source of different hematopoietic cells in the tumor
microenvironment and they could provide a new evidence of the chimeric origin of blood cells in the
tumor microenvironment.
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2. Results
2.1. Cancer Stem Cells Converted from miPSCs
Our lab has previously established a protocol for generating CSCs from miPSCs while using
conditioned media from different cancer cell lines. The conditioned media of human breast cancer
cell line BT549 cells was used to convert miPSCs into CSCs, CSCcmBT549 cells [12]. The CSCs
showed tumorigenic ability in vivo and the expression of stemness markers in addition to the ability to
differentiate into fibroblast like cells with the character of cancer associated fibroblasts. Here, we used
the primary cultured cells, which had been isolated from the primary tumor that was developed from
CSCcmBT549 cells and showed the characteristics of tumorigenicity and stemness. CSCcmBT549 cells
were maintained in the presence of a 10% conditioned medium without Leukemia Inhibitory Factor
(LIF), while miPSCs were cultured in the presence of LIF. In culture condition with LIF, miPSCs make
colonies and show green fluorescent protein (GFP) expression (Figure 1A,B), while the CSCcmBT549
cells proliferate and survive in the absence of LIF showing GFP expression under the Nanog promoter
indicate the expression of Nanog (Figure 1C,D). In contrast, miPSCs failed to survive and maintain
undifferentiated state in the absence of LIF, as was well demonstrated in previous reports [12,17].
CSCcmBT549 cells maintained the expression of stem cell markers, such as OCT3/4, Nanog, and Sox2.
Moreover, the expression of cancer stem cell markers, CD133 and CD44, elevated in CSCcmBT549 cells
when compared with those in miPSCs (Figure 1E,F). Flow cytometry also confirmed the expression of
stemness markers (Figure 1G–I).
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Figure 1. Morphology and Expression of GFP, stemness and cancer stem cell markers in CSCcmBT549
cells when compared with those in mouse induced pluripotent stem cells (miPSCs). (A,B) Representative
images of miPSCs colony morphplogy using the bright field and fluorescence showing the expression
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of GFP in culture media with LIF. Scale bars represent 50 µm. (C,D) Representative images of
CSCcmBT549 cells using bright field and fluorescence showing the expression of GFP in the cells after
selection by puromycin. Scale bars represent 50 µm. (E,F) Gene expression levels of stem cell markers,
OCT3/4, Nanog and Sox2 (E) and cancer stem cell markers, CD133 and CD44 (F) evaluated by RT-qPCR.
The gene expression levels normalized by GAPDH expression were compared between CSCcmBT549
cells and miPSCs. (G–I) Flow cytometry analysis for stemness markers, (G) OCT3/4 and GFP, (H) SOX2
and GFP, (I) ALDH1 and GFP. GFP level is in parallel with Nanog expression *** p < 0.001.
2.2. Non-Adherent Round Cells Emerging from CSCs
CSCcmBT549 cells have both GFP and puromycin resistance genes that are expressed under
Nanog promoter, allowing for eliminating differentiated and host-derived cells from CSCs after the
culturing of primary cells from mouse allografts. CSCs from the primary tumor were maintained in
miPSCs media with 10% conditioned media. The cells were washed after 24 h of culturing to remove
the non-adherent and dead cells. After 72 h of culturing, round floating or weak adherent like cells
were observed on the top of the adherent monolayer of CSCs (Figure 2B). Fixing and staining cells with
DAPI after 72 h showed that round like cells have nucleus staining positively with DAPI, and those
cells were smaller than adherent cells (Figure 2D–E). In the next step, the floating cells were collected
and found to have heterogeneous diameters with round morphology (Figure 2C). The viability of
non-adherent cells (NACs) was analyzed by flow cytometry while using Annexin V and 7-AAD and
showed that 86.5 ± 2% of floated cells were viable (Figure 2F).
2.3. NACs Have Hematopoietic Cells Characteristics
The NACs were analyzed by flow cytometry to examine the expression of hematopoietic
lineage markers while using the Lineage Cell Detection Cocktail in addition to the CD34 antibody.
The flow-cytometric analysis revealed that around 78.9 ± 15.6% of NACs were positive for lineage
markers, and 89.3 ± 1.5% were positives for CD34 (Figure 2H,J), in contrast of parental adherent cells
(Figure 2G,I).
Furthermore, Wright–Giemsa staining of NACs showed heterogeneous patterns that were similar
to different types of leukocytes, such as orange to pink granules in cytoplasm as eosinophils (Figure 2K),
dark bluish-purple granules and reddish-purple nuclei as basophils (Figure 2N), and violet nucleus
and light blue or light pink cytoplasm as monocytes (Figure 2L,M,O,P). The nuclei were also either
lobed, ellipsoidal, or round (Figure 2K–P). Immunofluorescence staining also confirmed the expression
of lineage markers, CD34, and c-Kit on the NAC surfaces in contrast to parental adherent cells that
were negative for lineage markers and CD34 and low positive for c.kit (Figure 3A–R). Consistent with
these findings, molecular phenotyping revealed that NACs expressed different hematopoietic cell
markers, such as CD34, CD38, CD10, c-Kit, CD90, and RUNX1 (Figure 4A).
NACs were also cultured on mouse embryonic fibroblast (MEFs) and semisolid media,
methylcellulose, to investigate their ability to form colonies. Culturing NACs on MEFs or
methylcellulose showed the ability of those cells to form colonies. However, the size of colonies on
MEFs was bigger than that on methylcellulose (Figure 4B–G).
Cancers 2020, 12, 82 5 of 17
Cancers 2019, 11, x 5 of 19 
 
 
Figure 2. Characterization of the non-adherent round cells. (A) Representative image of 
CSCcmBT549 after 24 h of seeding. (B) Representative images of CSCcmBT549 cells after 72 h of 
seeding, showing round non-adherent cells on the top of the monolayer of adherent cells. (C) Floating 
non-adherent cells collected from the culture of CSCcmBT549 cells. Scale bars for (A,B,C) represent 
100 μm. (D,E) Bright field and DAPI staining showing nuclei of round non-adherent cells (NACs) on 
the top of the monolayer adherent cells. Scale bars represent 16 μm. (F) Representative image of flow 
cytometry analysis of apoptosis assay by” Annexin V and 7-AAD kit” shows that the majority of the 
cells are viable while apoptotic and dead cells are less than 15%. This image is representative of at 
least three independent experiments. (G–J) Flow cytometry analysis for CD34 and hematopoietic 
Figure 2. Characterization of the non-adherent round cells. (A) Representative image of CSCcmBT549
after 24 h of seeding. (B) Representative images of CSCcmBT549 cells after 72 h of seeding, showing
round non-adherent cells on the top of the monolayer of adherent cells. (C) Floating non-adherent cells
collected fro the culture of CSCcmBT549 cell . Scale bars f r (A,B,C) repr sent 100 µm. (D,E) Bright
field and DAPI staining showing nuclei of round non-adherent cells (NACs) on the top of the monolayer
adherent cells. Scale bars represent 16 µm. (F) Representative image of flow cytometry analysis of
apoptosis assay by” Annexin V and 7-AAD kit” shows that the majority of the cells are viable while
apoptotic and dead cells are less than 15%. This image is representative of at least three independent
experiments. (G–J) Flow cytometry analysis for CD34 and hematopoietic lineage differentiation
markers (Lineage Cell Detection Cocktail-Biotin, where (G,I) are for adherent CSCcmBT549 cells and
(H,J) are for NACs. Each result is shown as a representative of at least three independent experiments.
(K–P) Wright–Giemsa staining of floating cells showing different diameters and staining patterns. Scale
bars represent 16 µm.
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Figure 3. Immunofluorescence staining of NACs. (A–F) Immunofluorescence staining showing both
adherent CSCcmBT549 cells (A–C) and floating cells (D–F) stained for lineage markers. (G–L) CD34
immunofluorescence staining showing both adherent CSCcmBT549 cells (G–I) and floating cells (J–L).
(M–R) c-kit immunofluorescence staining showing both adherent CSCcmBT549 cells (M–O) and
floating cells (P–R). Scale bars represent 16 µm.
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Figure 4. Molecular phenotyping and clonogenic test of NACs. (A) Agarose gel electrophoresis of NAC
transcripts amplified by RT-PCR. (B–E) Representative images of clonogenic test on MEFs, (B) MEFs
cells before seeding of NACs (C) MEFs and NACs cells on the day 1. (D,E) Representative images
of the colony of NACs after one week of culture on MEFs. F, G) Clonogenic test on semisolid media
(methylcellulose). Scale bars represent: (B,D) 100 µm, (C,F) 50 µm, and (E,G) 20 µm.
2.4. NACs Showed the Ability of Homing to Bone Marrow and Might Lead to Restoring Leukocytes in
Busulfan-Conditioned Mice
NACs were injected into the tail vein of Balb/c nude mice to assess the potential of clonogenicity
in vivo and the engraftment of NACs. Before the injection, CSC mB 549 cells were transfect d with a
plasmid expressing mCherry and stable transfectants were selected. Transfected CSCcmBT549 cells
expressed both GFP an mCherry (Supplementary Figure S1A–C). However, the GFP expression was
lost when the cells differentiate, since Nanog is a stemness marker. They expressed mCherry, which
enabled the tracking of daughter cells derivate from CSCcmBT549 cells (Supplementary Figure S1D–F).
The mice that were conditioned with busulfan were injected with two doses of NACs. Four weeks
after injection, the cell suspensions obtained from the bone marrow (BM) and the spleen showed red
fluoresce t cells (Supplementary Figure S1J–L,P–R). The engraftment of NACs an the presence of
NACs in the mouse BM were further confirmed by immunohistochemical staining with antibody
against mCherry, which showed strong positive staining of BM sections when compar d with those in
mice that were injected with PBS as controls (Figure 5D,E). Although the mCherry positive cells were
detected in BM cells after isolation while using fluorescence microscope and by immunohistochemical
staining of BM sections, there was a difference regarding the number of positive cells depending on
the method used to detect cells. It seemed that the number of mCherry positive cells in isolated cells
that were detected by fluorescence microscope is less than those in the BM sections that were stained
while using mCherry antibody (Figure 5E and Supplementary Figure S1L). Notably, the counting of
20 random fields of peripheral blood smears stained with Wright–Giemsa showed that the number of
white blood cells (WBC) was significantly higher in mice that were injected with NACs than in controls
injected with PBS (Figure 5F–H). Moreover, the PCR reaction confirmed the presence of cells that were
derived from NACs in the peripheral blood, which have a GFP gene, after four weeks of injection of
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NACs in the tail vein (Figure 5I). The increasing number of WBCs and the presence of cells derived
from NACs may reflect the ability of NACs to restoring and repopulating of WBCs through migration
and homing.
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Figure 5. Engraftment and homing of NACs in the bone marrow. (A) Schematic graphic of preparation
and injection of NACs. (B–E) Representative images for the sections of the bone marrow stained
with Hematoxylin and Eosin (B,C) and immunostained for anti- Cherry (D,E), where (B,D) are
sections of mice injected with PBS as contr ls and (C,E) are those from mice injected with NACs.
(F,G) Representative images of peripheral blood smears stained with Wrights–Giemsa, (F) for mice
injected with NACs and (G) for mice injected with PBS as controls. Red arrows indicate the WBCs.
(H) Average number of WBCs in 20 random fields of three independent peripheral blood smears stained
with Wrights-Giemsa. (I) Agarose gel electrophoresis of PCR products amplified from DNA samples
from peripheral blood after four weeks of injection of both mice injected with PBS as controls and mice
injected with NACs. *** indicate the p ≤ 0.001.
2.5. Differentiation of CSCs into Macrophages
We applied in vitro differentiation protocol to direct differentiation of CSCs into macrophages in an
attempt to evaluate the potential of adherent cancer stem cells to differentiate into specific hematopoietic
cell types. The differentiation was stimulated by adding IL3 and SCF to the culture media. After
12 days of differentiation, the expression of macrophage surface markers: F4/80, CD11b, CD14, and
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CD68 significantly increased (Figure 6A). Interestingly, the expression of CD14, which defines the
characteristic of macrophages, was approximately 40-fold higher in the differentiated cells than in the
undifferentiated CSCs. CD68 was considered as a marker of tumor associated macrophages elevated
approximately 100-fold. We further analyzed the subpopulation expressing F4/80 and CD11b in both
undifferentiated and differentiated CSCs by flow cytometry to evaluate the overall differentiation
process. The cells expressing F4/80 and CD11b after differentiation were found increasing to 15.2 ± 6.4%
and 11.7 ± 4.7% respectively (Figure 6B–G).
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Figure 6. Differentiation potential of CSCs into macrophages. (A) Gene expression levels of macrophage
markers (F4/80, CD11b, CD14, and CD68). The gene expression levels normalized by GAPDH expression
levels were relatively compared between the cells with/without stimulation of differentiation by IL3
Cancers 2020, 12, 82 10 of 17
and SCF. * p ≤ 0.05; *** p ≤ 0.001. Diff: differentiated cells, Undiff: undifferentiated cells. (B–G) Flow
cytometry analysis for F4.80 and CD11b. (B–D) Cells without stimulation of differentiation. (E–G) Cells
with stimulation of differentiation. (B,E) FSC and SSC distribution of gated cells. (C,F) F4.80 and
(D,G) CD11b. Each result is shown as a representative of at least three independent experiments.
(H–K) Representative images for CSC smears stained with Wrights–Giemsa. (H) For control and
(I,G,K) Cell smears after differentiation showing irregular shape with pseudopods (I,K), cytoplasmic
vacuolization (k), and lobed (I,K), or Ovid nucleus (J). Scale bars represent 16 µm.
Moreover, Wright–Giemsa staining showed that some of the CSCs exhibited the morphology of
macrophages after differentiation (Figure 6I–K). The irregular shape with pseudopods, with vacuoles
in cytoplasm and lobed or Ovid nucleus was observed. In contrast, the undifferentiated cells showed
dark purple staining in whole cells (Figure 6H).
3. Discussion
The characteristics of stemness in cells reflect the ability to perpetuate their lineage and give rise
to differentiated phenotypes. In the case of CSCs, cell phenotypes derived from CSCs are still under
investigation [21]. There is substantial evidence in favor of the multipotentiality and the ability of
CSCs to form tumor microenvironment along with other tissue components by providing different
cell phenotypes, such as endothelial cells and cancer-associated fibroblasts [12,22–24]. Hematopoiesis
includes many progenitor and cell types, which could take place in the bone marrow, the liver, or the
yolk sac, depending on the development stage [25]. Responding to the changes in the architecture
of tissue, paracrine and autocrine feedback loops of different cytokines and chemokines could direct
CSCs to different fates. It is well established that targeting CSCs reduces relapse and metastases in
cancer patients. Moreover, by combining CSCs, targeted therapies with conventional one tumors could
be eradicated [26]. Targeting stemness pathways and microenvironment components while using
stemness markers, or immunological approaches are some examples of recent efforts for designing
more effective cancer treatments [27,28]. Those strategies have proven to be valid and they limit
tumor progression, in addition to the reduction of tumor size [29,30]. New cells that arise from CSCs
could drive tumor phenotype, survival, and growth [31,32]. Here, we describe that CSCs could give
non-adherent cells with a phenotype common to hematopoietic cells.
Our lab has developed a unique method for obtain CSCs from iPSCs in the presence of conditioned
media from cancer cell lines mimicking tumor microenvironment. After conversion, the cells that
were injected into mice exhibited the ability to form malignant tumors, while iPSCs developed
non-malignant teratoma. Moreover, isolated cells from malignant tumors expressed cancer stem cell
markers and had ability to survive without LIF in culture media, while miPSCs failed to survive
without LIF [12,17–19,33].
CSCcmBT549 cells that were used as the CSCs in this paper were well isolated and selected in
the presence of puromycin allowing for eliminating all of the host-derived and differentiated cells.
By culturing the CSCs, we observed that floating cells, NACs, are arising from adherent cells. Our data
show that the NACs are viable and they do not adhere to gelatin-coated dishes unlike the parent cells.
Moreover, the NACs staining pattern and morphology were found to be quite similar to those of typical
white blood cells (WBCs). CSCs may have the ability to differentiate into early hematopoietic stem
cells, which eventually give different progenitors, since the NACs showed different Wright–Giemsa
staining patterns and expressed different markers of hematopoietic progenitors. Moreover, NACs
demonstrated the ability of homing to the bone marrow and surviving up to four weeks after injection
into the blood flow.
NACs could be a mixture of different hematopoietic progenitors and lineage cells, so that the
identification of all progenitors, which could exist in NACs, might be difficult. This hypothesis is
supported by the expression of different surface markers, such as CD10, CD34, CD38, c-kit, and
Runx1 in NACs, and by positive immunoreactivity to the mixture of antibodies specific to different
lineage-committed hematopoietic cells. Moreover, NACs that were able to migrate and home to the
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bone marrow after injection in the tail vein were confirmed by the detection of mCherry positive cells
in BM sections and cultured cells that were isolated from BM. However, there was a difference in the
number of positive cells between the two methods, which could be because of the difference in the
sensitivity between the fluorescence microscope and the immunohistochemical staining. The low
level of mCherry expression could be eliminated in the filter setting in the fluorescence microscope
in contrast to immunohistochemical staining, which could amplify these signals and present it as
low positive staining for the mCherry antibodies (Figure 5E). Another possible explanation of this
difference could be because BM sections were prepared from femur bones, while BM cells were isolated
from both femur and tibia bones. Yet, both methods detected the homing of injected NACs to the bone
marrow. This is of particular interest, because NACs were shown to contain not only differentiated cells,
but also hematopoietic progenitors with the potential of homing to the bone marrow and surviving.
Another interesting observation was the increasing of WBCs number in peripheral blood for the mice
that were injected with NACs in contrast of those in the control mice. At the same time, the WBCs had
shown to have the GFP gene (Figure 5I), which confirms that there are some cells derived from NACs
in the mice peripheral blood after four weeks of the injection. Thus, NACS could be responsible for
the repopulation of peripheral blood cells being producing blood cells. However, more investigation
could provide more explicit evidence for this association by using additional cell tracking methods.
From a perspective of cell biology, the interaction between tumor cells and other cellular
components of tumor microenvironments is the main enforcement of spreading and proliferation
of tumors [34]. Some recent reports showed that solid tumor progress could result in changes in
peripheral blood cells, although there is a lack of studies on the ability of solid CSCs or cell lines
derived from solid cancers to differentiate into hematopoietic cells. Ivana Z Matic´ et al. showed that
there are changes in the granulocyte and lymphocyte percentages in patients with metastatic colorectal
cancers [35]. While Rocca et al. showed an increase in peripheral blood natural killer cells proportions
in patients with colorectal cancer [36]. However, the origin of those cells has not been investigated and
is supposed to be all derived from the bone marrow.
On the other hand, the origin of tumor-associated macrophages (TAMs) now is still debated.
The well-believed concept of circulating monocytes as the origin of TAMs has recently changed
and embryonic-derived macrophages were considered as major suppliers to the tissue-resident
macrophages [8]. Moreover, several cell lines that were derived from solid cancer and human tumor
samples have been shown to be able to generate erythroid cells [16]. In the same context, polyploid
giant cancer cells with stem cell-like characteristics have also been shown to have the ability to give
erythroid cells [16,37,38]. Our data here also show that CSCs could be differentiated into macrophages
responding to the specific factors, such as IL3 and SCF. This result could provide new insights into the
origin of TAMs, as driven by cancer stem cells.
Collectively, perceptions are changing regarding the association between different types of blood
cells and solid cancer cells. Within the context, the cancer stem cell model suggests the differentiation
potential of CSCs into different phenotypes in the tumor microenvironment. Our data could shed the
light on a new area of relationship between CSCs and hematopoietic cells in the response to tumor
microenvironments. This study could encourage more investigation regarding the ability of solid
cancer cells to generate more specific types of hematopoietic progenitors or differentiated cells.
4. Materials and Methods
4.1. Cell Culture
Cancer stem cells, CSCcmBT549 cells, were obtained by the conversion of miPSCs (iPS
MEF-Ng-20D-17) cells in the presence of conditioned medium from human breast cancer cell line
BT549 cells (ATCC HTB-122), followed by the primary culture of the tumor formed in Balb/c nude
mice [12]. The stemness and tumorigenicity of CSCcmBT549 cells had previously been confirmed.
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The CSCcmBT549 cells were maintained in 0.1% gelatin coated 60 mm-dishes with DMEM media
(Wako, Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS), 0.1 mM MEM non-essential
amino acids (NEAA) (Gibco, Waltham, MA, USA), 2 mM L-glutamine (Nacalai Tesque, Kyoto,
Japan), 50 U/mL penicillin/streptomycin, 0.1 mM 2-mercaptoethanol (Millipore, MA, USA), and 10%
conditioned media from BT549 cells. Host derived cells were removed in the presence of 1 ug/mL
puromycin (Sigma-Aldrich, St. Louis, MO, USA) in the culture medium, since CSCcmBT549 cells have
both puromycin resistance and GFP gene expression under Nanog promoter. BT549 cells were cultured
in RPMI-1640 medium (Wako, Tokyo, Japan) containing 10% FBS (Gibco, Waltham, MA, USA), when
the cells reached 70–80% confluence, the media was changed to RPMI-1640 containing 5% FBS after
48 h to prepare the conditioned media (CM). Subsequently, CM was collected, centrifuged at 1000 g for
10 min, and the supernatant was then filtered through 0.45 µm filters (Sartorius, Göttingen, Germany).
After confirming no BT549 cells, the CM was used for the maintenance of CSCs.
4.2. Collection and Culture of NACs
CSCcmBT549 cells, 2 × 106 cells, were seeded on T75-flasks (TPP Techno, Switzerland) coated
with 0.1% gelatin in the same media mentioned above. After 24 h of culture, the cells were washed
with phosphate-buffered saline (PBS) and fresh media was added. At day 3, the floating non-adherent
cells were harvested in 50 mL-centrifuge tubes (Corning, New York, NY, USA), centrifuged at 500g
for 10 min., suspended in 0.5 mL of MyeloCultTM M5300 media (stem cell technology, Vancouver, BC,
Canada), and then seeded on 60-mm dishes coated with 0.1% gelatin. After 24 h, the non-adherent
cells were transferred to new 60-mm dishes that were coated with 0.1% gelatin to remove CSCcmBT549
cells remained adherent.
4.3. RNA Extraction, cDNA Synthesis, and PCR
Total RNA was extracted from cells while using TRIzol Reagent (Thermo Fisher, Waltham,
MA, USA) and then treated with DNase I (Promega, Madison, WI, USA) to remove genomic-DNA
contamination from the samples. The RNA purity was evaluated by A260/A280 ratio while using
NanoDrop (GE Healthcare, Chicago, IL, USA) to confirm in the range of 1.8 to 2. According to the
instructions that were provided with the kit, 5 µg of RNA was reverse transcribed while using the
GoScript™ Reverse Transcription System (Promega, Madison, WI, USA). The PCR reactions were
performed while using the 2× Taq master mix (New England BioLabs, Ipswich, MA, USA) and the
transcript products were visualized on agarose gel while using ethidium bromide (Sigma Aldrich,
St. Louis, MO, USA) and 100 pb ladder (Takara, Shiga, Japan). Quantitative real-time PCR (RT-qPCR)
was performed with LightCycler® 480 and Light Cycler 480 SYBR Green I Master (Roche, Basel,
Switzerland), according to the manufacturer’s instructions. The melting curve analysis was also
undertaken to check the specificity of amplification. GAPDH was employed as a reference gene and
GAPDH expression levels normalized all data. Primers were designed with bioinformatics tools,
such as BLAST (NCBI, Bethesda, MD, USA) and Primer3 tool at http://bioinfo.ut.ee/primer3-0.4.0/,
ensuring the primer specificity (Table 1).
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Table 1. Sequences of primers used in the study.
Gene Accession Number Forward Primer Reverse Primer
GAPDH NM_008084 AACGGCACAGTCAAGGCCGA ACCCTTTTGGCTCCACCCTT
Nanog NM_028016.3 AGGGTCTGCTACTGAGATGCTCTG CAACCACTGGTTTTTCTGCCACCG
OCT3/4 NM_013633.3 TCTTTCCACCAGGCCCCCGGCTC TGCGGGCGGACATGGGGAGATCC
SOX2 NM_011443.4 TAGAGCTAGACTCCGGGCGATGA TTGCCTTAAACAAGACCACGAAA
CD133 NM_001163578.1 CCTTGTGGTTCTTACGTTTGTTG CGTTGACGACATTCTCAAGCTG
CD44 NM_009851.2 AGAAAAATGGCCGCTACAGTATC TGCATGTTTCAAAACCCTTGC
CD90 NM_009382.3 TGCAGCTAGGGGAGTCCAGAAT TCCAGGCGAAGGTTTTGGTT
c.kit NM_021099.3 CGGACAGCACCAAGCACATTTACTC AACCATCACAGAAGCCAGAAGGACG
CD34 NM_001111059.1 TGCTGCATCTAAATAACTTGAC AGGGATCCCAGAGGTAACTG
RUNX1 NM_001111021.2 CTGCCCATCGCTTTCAAGGTG CTATGGTAGGTGGCAACTTGTGG
CD38 NM_007646.5 TGAGAGATCAGAACTGCCAGG GTGTCCTCCAGGGTGAACAT
CD10 NM_008604.4 GCTAGAAGTCATTTTGAAAGATGTCCT AGTGCCATATGTTTGATCCCAGT
CD11b NM_001082960.1 TACGTAATTGGGGTGGGAA GTGCCCTCAATTGCAAAGAT
CD14 NM_009841.3 CTCTGTCCTTAAAGCGGCTTAC GTTGCGGAGGTTCAAGATGTT
F4/80 NM_010130.4 CACCGGTATAGACAAGACTGACA TCTCACCATCAGGAAGAGCA
CD68 NM_009853.1 ACTTCGGGCCATGTTTCTCT GCTGGTAGGTTGATTGTCGT
GFP GACAAGCAGAAGAACGGCATCAAGG CTCAGGTAGTGGTTGTCGGGCAG
4.4. Flow Cytometry
The NACS were washed with cold PBS, blocked with mouse FcR blocking reagent (Miltenyi
Biotec, Bergisch Gladbach, Germany) for 10 min at 4 ◦C, and then stained with lineage cell detection
cocktail-biotin antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) and anti-CD34 rabbit antibody
(Santa Cruz Biotechnology, Dallas, TX, USA). After incubation and washing, the cells were incubated
with the secondary antibodies, Alexa Fluor 647 goat anti-rabbit IgG, and APC labeled anti-Biotin
antibody (Miltenyi Biotec, Bergisch Gladbach, Germany). NACs were also stained with PE Annexin
V Apoptosis detection kit, according to the manufacturer’s protocol (BdBiosciences, San Jose, CA,
USA) for the detection of necrotic, apoptotic, and live cells. CSCcmBT549 cells that were stained
with anti-Oct3/4 antibody (Cell Signaling Technology, Danvers, MA, USA), anti-Sox2 (Cell Signaling
Technology, Danvers, MA, USA), anti-ALDH1 (Abcam, Cambridge, United Kingdom), anti-F4/80
antibody (Abcam, Cambridge, United Kingdom), and anti-CD11b (Santa Cruz Biotechnology, Dallas,
TX, CA, USA). Alexa Fluor 647 Goat anti-rat IgG (Abcam, Cambridge, United Kingdom) and APC rat
anti-mouse IgG (BioLegend, San Diego, CA, USA) were used as the secondary antibodies. The cells
were run on the flow cytometer Accuri C6 Plus (BD Bioscience, San Jose, CA, USA) and then analyzed
by Flowjo software, excluding the patterns of cell debris and aggregates based on scatter signals.
4.5. Wright-Giemsa Staining
The NACs were centrifuged at 800 g for 10 min., washed with PBS, and then suspended in PBS.
The smears of cell suspension were prepared on slide glass that was coated with poly-L-lysine solution
0.1% (Sigma-Aldrich, St. Louis, MO, USA). The slides were left to dry, fixed with methanol, and then
stained with Wright–Giemsa solution (Muto Pure Chemicals, Japan).
4.6. Immunofluorescence Staining
NACs smeared on slides and adherent CSCs cultured on cover slides that were coated with
0.1% gelatin were fixed while using 4% paraformaldehyde (Wako, Tokyo, Japan) for 20 min., washed
two times with PBS, and then blocked using PBS containing 10% FBS at room temperature for one
hour. The cells were then incubated overnight at 4 ◦C with primary antibodies, lineage cell detection
cocktail-biotin antibody (Miltenyi Biotec, Bergisch Gladbach, Germany), anti-CD34 antibody (Santa
Cruz Biotechnology, Dallas, TX, USA), and anti-CD117/c-kit (Zytomed systems, Berlin, Germany).
After incubation, the cells were washed three times with PBS and then incubated with secondary
antibodies, Alexa Fluor 555 labeled anti rabbit IgG goat antibody (Thermo Fisher, Waltham, MA, USA),
APC labeled anti-Biotin antibody (Miltenyi Biotec, Bergisch Gladbach, Germany), and PE labeled
anti-mouse IgG goat antibody (BioLegend, San Diego, CA, USA) for 1 h. Thereafter, they were washed
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three times with PBS and then mounted with VECTASHIELD® Antifade Mounting Medium with
DAPI (Vector Laboratories, Burlingame, CA, USA). The cells were observed with the Olympus FV-1000
microscope (Olympus, Tokyo, Japan).
4.7. Clonogenic Assay
MEFs (Reprocell, Japan) were seeded on 60-mm dishes at a density of 5 × 105 cells with
DMEM media containing 10% FBS to evaluate the ability of NACs to form colonies on mouse
embryonic fibroblasts (MEFs). After 24 h, the MEFs were washed with PBS and fresh DMEM media
containing 10% FBS, 0.1 mM MEM non-essential amino acids (NEAA), 2 mM L-glutamine, 50 U/mL
penicillin/streptomycin, 0.1 mM 2-mercaptoethanol, and 10% conditioned media were added and
1 × 105 NACs were seeded on the top of MEFs. One week after NACs seeding, colony formation was
assessed under inverted microscope IX81 (Olympus, Tokyo, Japan). MethoCult™ GF M3434 media
(Stem Cell Technology, Vancouver, BC, Canada) was employed for the clonogenic test on semisolid
media. The NACs were cultured in MethoCult™ media according to the manufacturer’s protocol.
Colony forming ability was evaluated two weeks after.
4.8. Introduction of mCherry Gene
mCherry expressing plasmid pAcmCherry-C2 was constructed by replacing AcGFP1 gene in the
plasmid pAC-GFP1-C2 (Takara, Shiga, Japan) with mCherry gene. Twoµg of pAcmCherry-C2 DNA was
transfected to 2 × 106 CSCcmBT549 cells that were suspended in 600 µL of Gene Pulser electroporation
buffer (Bio-Rad Laboratories, Hercules, CA, USA). The cell suspension was electroporated in 0.4-cm
gap-cuvette by Gene Pulser II (Bio-Rad Laboratories, Hercules, CA, USA) and the cells were seeded in
gelatin-coated dishes. Afterwards, G418 resistant transfectants were selected by culturing for one to
two weeks in the presence of G418 (Wako, Tokyo, Japan) at a concentration of 300 ug/mL. mCherry- and
GFP-positive undifferentiated cells were both further selected in the presence of 1 ug/mL puromycin
(Sigma-Aldrich, St. Louis, MO, USA) for seven days. The media were changed daily.
4.9. Animal Experiments
Female Balb/c nude mice were purchased from (Charles River Laboratories, Wilmington, MA,
USA) and then kept under pathogen-free conditions. All of the experiments were conducted according
to the animal care and use committee of Okayama University under the project license OKU-2016252.
Mice received busulfan (90 mg/kg) (LKT Laboratories, St. Paul, MN, USA) by intraperitoneal injection of
30 mg/kg/day for three days. On day 4, the mice were divided into two groups. A total of 1 × 107 NACs
expressing mCherry were washed with sterile PBS, suspended in 100 uL of PBS, and then injected into
the tail vein of one group, whereas PBS was injected into the tail vein of the other group of mice as a
control. After one week, another 5 × 106 NACs were injected to increase the chance of homing.
Four weeks after injection, the bone marrow from femur and tibia bones, the peripheral blood,
and spleens were obtained. The smears of peripheral blood were stained with Wright–Giemsa as
described above. The BM samples were treated with red blood cell (RBC) lysis buffer (BioLegend,
San Diego, CA, USA), washed with PBS, suspended in 0.5 mL of DMEM with 15% FBS, and then
seeded in six-well plate while using DMEM supplemented with 15% FBS, 0.1 mM MEM NEAA, 2 mM
L-glutamine, and 0.1 mM 2-mercaptoethanol. The spleen samples were chopped and suspended in
dissociation buffer, as described previously [17]. Cells were observed under a fluorescence inverted
microscope IX81 (Olympus, Tokyo, Japan).
4.10. DNA Extraction
Four weeks after injection, peripheral blood samples were obtained from mice, DNA was extracted
while using blood and cell culture DNA mini kit (Qiagen, Hilden, Germany) according to the kit
instructions, and the PCR reactions were performed as the same mentioned above with GAPDH and
GFP primers. Primer sequences are shown in (Table 1).
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4.11. Histological Analysis and Immunohistochemistry
Extracted femur bones were decalcified while using 14% EDTA (Wako, Tokyo, Japan), embedded
into paraffin using standard histologic techniques and sectioned at 5 µm of thickness. The sections were
deparaffinized, rehydrated and stained with hematoxylin-eosin (Hematoxylin solution, Sigma-Aldrich,
St. Louis, MO, USA; 0.5% Eosin Y, Wako, Tokyo, Japan) for histological analysis. For the
immunohistochemistry of mCherry, the antigen retrieval was carried out by using sodium citrate buffer
(pH 6.0) with 0.05% Tween 20 for 15 min by a standard microwave heating technique. After cooling
down, hydrogen peroxide blocking and Ig blocking were undertaken while using 3% hydrogen peroxide
and Ig blocking reagents (Vector Laboratories, Burlingam, CA, USA). After overnight incubation of
sections with anti-mCherry, rabbit (Funakoshi, Tokyo, Japan) at 4 ◦C, the ABC staining kit and DAB
(3,3′-diaminobenzidine) substrates (Vector Laboratories, Burlingame, CA, USA) were used for the
detection of mCherry, respectively. The sections were counter-stained using hematoxylin and mounted
with Micromount (Leica Camera AG, Wetzlar, Germany). The staining was evaluated under light
microscopy (FSX100, Olympus, Tokyo, Japan).
4.12. Differentiation of CSCs into Macrophages
CSCcmBT549 cells were maintained, as described above. Differentiation was performed on
a gelatin-coated dishes in DMEM containing 10% FBS, 0.1 mM MEM NEAA, 2 mM L-glutamine,
50 U/ml penicillin and streptomycin, 0.1 mM 2-mercaptoethanol, 10% conditioned media, 30 ng/mL
murine stem cell factor (SCF) (PeproTech, Rocky Hill, NJ, USA), and 10 ng/mL murine interleukin-3
(IL3) (PeproTech, Rocky Hill, NJ, USA). The cells were passaged when it reached approximately 80%
confluence. After 12 days, cells were analyzed for macrophage markers.
4.13. Statistical Analysis
Statistical analyses were performed while using the Prism Software version7 (Graph Pad Software,
San Diego, CA, USA). The data are presented as mean ± SD. Statistical comparisons between
experimental groups were analyzed by a T-test and p < 0.05 considered as statistically significant.
5. Conclusions
Our data demonstrate that CSCs converted from miPSCs can generate cells with hematopoietic
characteristics and might have the ability to repopulate peripheral blood by migration and homing to
the bone marrow after injection to the blood. CSCs derived hematopoietic cells could also contribute
to the tumor microenvironment; therefore, further studies on the mechanisms by which CSCs give
NACs and how those cells act together with other microenvironment components may shed light on
new mechanisms of the plasticity of CSCs and their adaption to the tumor microenvironment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/1/82/s1,
Figure S1: Stable transfection of CSCcmBT549 with mCherry expression plasmid and positive mCherry isolated
cells from mice.
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